Showing results (521-530 of 538) with videos related to

Sort By:
Pageof 54
JAMA Ophthalmology|April 24, 2020
Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of PrematurityDavid K Wallace, Raymond T Kraker, Sharon F Freedman, et al.
Frontiers in Oncology|August 22, 2022
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLCRachel Evans, Kelvin Lee, Paul K Wallace, et al.
JAMA Ophthalmology|April 28, 2017
Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing StudyDavid K Wallace, Raymond T Kraker, Sharon F Freedman, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|September 9, 2020
Circulating CD14<sup>+</sup> HLA-DR<sup>lo/-</sup> monocytic cells as a biomarker for epithelial ovarian cancer progressionAshley E Stenzel, Scott I Abrams, Janine M Joseph, et al.
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus|February 27, 2014
Office probing for treatment of nasolacrimal duct obstruction in infantsAaron M Miller, Danielle L Chandler, Michael X Repka, et al.
European Radiology|November 30, 2021
Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR Uterine and Ovarian Cancer Disease-Focused Panel and the ESUR Female Pelvic Imaging Working GroupAtul B Shinagare, Elizabeth A Sadowski, Hyesun Park, et al.
Rheumatology (Oxford, England)|February 2, 2022
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapyAnkoor Shah, Jan Storek, Rob Woolson, et al.
The Journal of Frailty & Aging|March 10, 2020
Moving Towards Common Data Elements and Core Outcome Measures in Frailty ResearchJ Muscedere, J Afilalo, I Araujo de Carvalho, et al.
JAMA Ophthalmology|May 7, 2026
Web-Based Amblyopia Decision Support ToolAllison I Summers, Stanley W Hatch, Sarah R Hatt, et al.
Cancer|February 14, 2022
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 studyPallawi Torka, Othman S Akhtar, Nishitha M Reddy, et al.
Pageof 54